As lung maturity increases, these lamellar bodies are released into the amniotic fluid, where their concentration can be accurately measured. A higher lamellar body count indicates sufficient surfactant production and reduced risk of neonatal respiratory distress syndrome (RDS).

The LBC test is widely valued because it is:

• Rapid and cost effective
• Minimally sample dependent
• Performed on standard haematology analyzers
• Clinically validated for predicting lung maturity

Healthcare providers commonly request this test in cases of preterm labor, pre eclampsia, diabetes in pregnancy, or when elective delivery is planned before 39 weeks. Results assist clinicians in making informed decisions regarding delivery timing and neonatal care preparation.

Lamellar Body Count testing is non invasive to the fetus (performed on collected amniotic fluid) and is recognized as an efficient alternative to more complex surfactant assays. When interpreted alongside clinical findings, LBC provides essential insight into fetal pulmonary development and neonatal outcome readiness.

Lung maturity and cumulative damage

Lungs do not regenerate like skin. Damage adds up over time. Monitoring exposure and lung health helps slow or prevent long term damage that shortens working life and quality of life. Lung cancer and many chronic lung diseases do not show symptoms in the early stages.

Laboratory testing and biological monitoring help organisations:

• Understand actual chemical absorption in the workforce
• Detect exposure across inhalation, skin contact, and ingestion
• Identify individual and task specific risk variations
• Support early intervention before health effects develop
• Used correctly, lab testing strengthens exposure control
• Respiratory infections can mask or worsen underlying occupational lung problems.

Download document